[PTH-replacement therapy in hypoparathyroidism : what benefits ?]

Area of Science:

• Endocrinology
• Rare Diseases
• Pharmacology

Background:

• Hypoparathyroidism is a rare endocrine disorder with significant long-term complications.
• Conventional treatment with calcium and vitamin D analogues has limitations, including hypercalciuria.
• Recent advances include hormonal substitution therapy with recombinant human parathyroid hormone (rhPTH) (1-84).

Purpose of the Study:

• To evaluate the efficacy and safety of rhPTH (1-84) in managing hypoparathyroidism.
• To compare rhPTH (1-84) therapy with conventional treatment regarding therapeutic targets and complications.

Main Methods:

• Review of recent publications on hypoparathyroidism progression and treatment.
• Analysis of data on patients treated with rhPTH (1-84) versus conventional therapy.
• Assessment of serum calcium levels, medication requirements, and 24-hour urinary calcium excretion.

Main Results:

• rhPTH (1-84) therapy led to a significant reduction (≥50%) in calcium and active vitamin D requirements.
• Serum calcium levels were maintained effectively with rhPTH (1-84) treatment.
• rhPTH (1-84) was associated with decreased 24-hour urinary calcium excretion and preserved renal function.

Conclusions:

• rhPTH (1-84) represents a major therapeutic advance for hypoparathyroidism.
• This hormonal substitution therapy improves treatment efficacy and reduces hypercalciuria.
• rhPTH (1-84) offers a valuable option for managing hypoparathyroidism, preserving renal health.